Phaseline

Companies › EXACT Therapeutics

EXACT Therapeutics: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
PS101
Acoustic cluster therapy agent for combination with ultrasound
–Phase 2Locally Advanced Pancreatic AdenocarcinomaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06850623PS101Phase 2Locally Advanced Pancreatic AdenocarcinomaOncologyDec 2026

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Shanghai Guangsheng Biopharmaceutical VIVUS Panbela Therapeutics Apollomics Elevar Therapeutics

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.